Innate ends Ph1b in peripheral T cell lymphoma; Layoffs at NextCure

21 Mar 2024

Phase 2ImmunotherapyPhase 1

Plus, news about Evommune, Maruho and Nouscom: Innate Pharma gives up on Phase 1b trial for cancer drug: The company was evaluating lacutamab as a monotherapy in KIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma KIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma. Innate said it’s not planning to restart recruitment in the trial after a clinical hold was put into place for studies assessing the drug in PTCL and cutaneous T cell lymphoma after a patient death was reported in the latter. It cited a lack of “meaningful clinical activity” for lacutamab in the PTCL study evaluating the drug as a monotherapy. It is still being studied in combination with chemo in a Phase 2 trial in PTCL. — Katherine Lewin

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

NextCure, Inc.

Nouscom AG

Innate Pharma SA

[+1]

Indications

Peripheral T-Cell LymphomaNeoplasmsCutaneous T-Cell Lymphoma

Targets

KIR3DL2

Drugs

Lacutamab

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.